File Name : figs1.tif

Caption : figure s1. superimposition of ligands between x-ray structure (black) and gold docking (green). jak2 complexed with tofacitinib (a) and egfr-tk complexed with erlotinib (b).  

File Name : figs2.tif

Caption : figure s2. ic50 curves of compounds and know drugs towards focused cells (a) tf1, hel and (b) a549, a431. data are represented as means ± sem of triplicate experiments.

File Name : figs3.tif

Caption : figure s3. cytotoxicity of compounds and know drugs towards vero cells. data are represented as means ± sem of triplicate experiments.

File Name : figs4.tif

Caption : figure s4. kinase inhibitory activity screening of compounds towards jak2 and egfr-tk at 1 μm. data are represented as means ± sem from duplicate independent experiments (n=2). * p ≤ 0.05 and *** p ≤ 0.001 vs. erlotinib in egfr-tk.

File Name : figs5.tif

Caption : figure s5. the fitness scores of focused thiazole derivatives towards jak2 and egfr-tk.

File Name : figs6.tif

Caption : figure s6. ic50 of kinase inhibitory activity of compounds towards jak2 and egfr-tk. data are represented as means ± sem from triplicate independent experiments (n=3). ** p ≤ 0.01 and **** p ≤ 0.0001 vs. erlotinib in egfr-tk.